Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase EARLY_PHASE1 4Phase 3 3Phase 1 3Phase 2 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 7Unknown 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7Leukemia, Myeloid, Acute 6Carcinoma, Hepatocellular 6Neoplasm Metastasis 5Colorectal Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Rectal Neoplasms 4Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Hematologic Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acute Kidney Injury 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1

Interventions

blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Myasthenia Gravis × Clear all
NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡